Home | IWG WG

Bodies: IWG WG

9 / 9 results found

Prophylactic and early outpatient treatment of COVID-19 in patients with kidney disease: considerations from the Immunonephrology Working Group of the European Renal Association (ERA-IWG)

March 07, 2023

IWG WG

The role of complement in glomerulonephritis: are novel therapies ready for prime time?

Speaker
Jonathan Barratt, United Kingdom

Panellists
Cees van Kooten, The Netherlands
Eleni Frangou, Cyprus

Moderator
Annette Bruchfeld, Sweden

Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from ERA-IWG and EUVAS

March 04, 2022

IWG WG

The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021

December 09, 2021

IWG WG

The management of membranous nephropathy – an update

November 08, 2021

IWG WG

Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases

March 09, 2021

IWG WG

The switch from proteasome to immunoproteasome is increased in circulating cells of patients with fast progressive immunoglobulin A nephropathy and associated with defective CD46 expression

June 24, 2020

IWG WG

Recommendations for the management of patients with immune-mediated kidney disease during the severe acute respiratory syndrome coronavirus 2 pandemic

May 23, 2020

IWG WG

2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis

March 27, 2020

IWG WG

Discover the ERA endorsed events

Together we can shape the future of Nephrology

Start planning your agenda for the 60th ERA Congress

Annual Report 2020

Discover the selection of the summary reports of the 59th ERA Congress

An easy recipe from Turkey

The burden of anaemia in CKD patients and the unme...

Webcast available!

Suggestions

Bodies: IWG WG

{%TITLE%}

{%TITLE%}

Prophylactic and early outpatient treatment of COVID-19 in patients with kidney disease: considerations from the Immunonephrology Working Group of the European Renal Association (ERA-IWG)

The role of complement in glomerulonephritis: are novel therapies ready for prime time?

Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from ERA-IWG and EUVAS

The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021

The management of membranous nephropathy – an update

Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases

The switch from proteasome to immunoproteasome is increased in circulating cells of patients with fast progressive immunoglobulin A nephropathy and associated with defective CD46 expression

Recommendations for the management of patients with immune-mediated kidney disease during the severe acute respiratory syndrome coronavirus 2 pandemic

2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis